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Abstract
HLA-G is a natural tolerogenic molecule involved in the best example of tolerance to foreign tissues there is: the maternal-
fetal tolerance. The further involvement of HLA-G in the tolerance of allogeneic transplants has also been demonstrated and
some of its mechanisms of action have been elucidated. For these reasons, therapeutic HLA-G molecules for tolerance
induction in transplantation are actively investigated. In the present study, we studied the tolerogenic functions of three
different HLA-G recombinant proteins: HLA-G heavy chain fused to b2-microglobulin (B2M), HLA-G heavy chain fused to
B2M and to the Fc portion of an immunoglobulin, and HLA-G alpha-1 domain either fused to the Fc part of an
immunoglobulin or as a synthetic peptide. Our results demonstrate the tolerogenic function of B2M-HLA-G fusion proteins,
and especially of B2M-HLA-G5, which were capable of significantly delaying allogeneic skin graft rejection in a murine in vivo
transplantation model. The results from our studies suggest that HLA-G recombinant proteins are relevant candidates for
tolerance induction in human transplantation.
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Introduction
Since the first successful kidney allo-transplantation in human
beings in 1952, the development of treatments limiting acute
allograft rejection has been the purpose of intense investigations.
Even though the discovery of immunosuppressive molecules such as
Cyclosporin A dramatically reduced acute allograft rejection cases,
their action on chronic allograft rejection is not optimal. Moreover,
besides their lack of efficiency on chronic allograft rejection, these
immunosuppressive treatments have side effects including high
susceptibility to infections, and renal and neural toxicity.
Among the biological molecules involved in the induction of
tolerance that have been characterized over the past years, the
non-classical HLA class I Human Leukocyte Antigen G molecule
(HLA-G) has unique features that make it an ideal candidate for
the development of new therapies in transplantation.
HLA-G (reviewed in [1,2]) is characterized by seven isoforms
which derive from the alternative splicing of a unique primary
transcript, by a very low amount of polymorphism, and by an
expression which is restricted to fetal trophoblast cells, adult
epithelial thymic cells, cornea, erythroid and endothelial cell
precursors, and pancreatic islets. HLA-G may also be pathologically
expressed by (i) non-rejected allografts [3,4], (ii) lesion-infiltrating
antigen presenting cells (APC) during inflammatory diseases [5,6],
and (iii) tumor tissues and their tumor infiltrating APC [7–11].
HLA-G is further expressed by (iv) monocytes in multiple sclerosis
[12], and by (v) monocytes and T cells in viral infections [13–15].
HLA-G is a potent tolerogenic molecule that strongly inhibits
the function of immune cells. Indeed, HLA-G inhibits NK cell and
cytotoxic T lymphocyte cytolytic activity [16,17], CD4
+ T cell
alloproliferative responses [18], T cell and NK cell ongoing
proliferation [18–20], and dendritic cell maturation [21,22].
Furthermore, HLA-G was shown to induce regulatory T cells
[18,23]. HLA-G mediates its functions by interacting with three
inhibitory receptors: ILT2 (CD85j/LILRB1) which is expressed by
B cells, some T cells, some NK cells and all monocytes/dendritic
cells [24], ILT4 (CD85d/LILRB2) which is expressed by myeloid
cells [25], and KIR2DL4 (CD158d) [26] which is expressed by
some peripheral and decidual NK cells.
The efficiency of the HLA-G binding to its receptors and the
delivery of potent inhibitory signals have been shown to depend on
HLA-G dimerization [27]. Biochemical studies indicate that HLA-
G dimerization occurs through disulfide-bond formation between
unique cysteine residues localized in position 42 of the HLA-G
alpha-1 domain (C42). Point mutation of C42 in Serine, which
leads to the exclusive expression of HLA-G monomers demon-
strated that HLA-G dimers, but not HLA-G monomers, carry
HLA-G tolerogenic function [27,28].
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trophoblast cells, where it confers protection against the mother’s
immune system. This mechanism of natural tolerance in a semi-
allogeneic context has led to investigate the potential role of HLA-
G in transplanted patients (reviewed in [2]). To date, clinical
studies have demonstrated that HLA-G expression may be
induced in some heart, kidney, liver/kidney, lung, pancreas, and
kidney/pancreas transplanted patients. Statistical analyses indicate
that the presence of HLA-G in plasma and biopsies of transplanted
patients correlates with a decreased number of acute rejection
episodes and with no chronic rejection, as first described for heart
transplants [3,29].
The direct role of HLA-G in transplantation in vivo was
evidenced by skin allotransplantation in HLA-G transgenic mice
or in wild-type mice pre-treated with HLA-G tetramer-coated
beads. In both experiments the presence of HLA-G significantly
delayed skin allograft rejection [30,31].
For these reasons, and also because it already contributes to the
best example of successful tolerance there is: the maternal-fetal
tolerance, therapeutic HLA-G molecules for transplantation are
actively investigated. Yet, the use of HLA-G molecules as
therapeutic agents faces several hurdles, among which the
problems of structure and stability. Indeed, HLA-G is a
trimolecular complex composed of a heavy chain of 3 globular
domains non-covalently associated with the b2-microglobulin
(B2M) and a peptide which is active only as a multimer.
Here, we evaluated (i) the tolerogenic function of two types of
HLA-G homodimers (C42-C42 dimers vs Fc-Fc dimers), (ii)
whether the alpha-1 domain of HLA-G which is common to all
HLA-G isoforms could carry a tolerogenic function by itself as it
was originally postulated, and (iii) whether the trimolecular
complex that constitutes HLA-G could be stabilized by fusing
B2M to HLA-G heavy chain while retaining its tolerogenic
properties.
Our results demonstrate the tolerogenic function of all
investigated dimeric forms of HLA-G recombinant proteins in
vitro and in vivo, and especially that of the B2M-HLA-G5 dimers in
vivo, but do not fully support a tolerogenic function for the alpha-1
domain of HLA-G in human beings, even dimeric.
Materials and Methods
Engineering of HLA-G fusion proteins
B2M-HLA-G1s-Fc (b2-microglobulin fused to the extra-
cellular part of HLA-G1 and to the Fc part of a human
IgG). T h es e q u e n c eco d i n gf o rt h eh u ma nb2-microglobulin (B2M)
was amplified by PCR with the primers B2M_Sig_Mlu-I_Sph-I_F
and B2M-Link-a1_R (Table 1). The B2M_Link-a1_R primer, which
is reverse complementary to the B2M coding sequence, is constituted
of three parts: B2M 39 sequence excluding the stop codon, fused to a
sequence coding for a (GGGGS)62 linker, fused to the reverse
complementary sequence of the HLA-G alpha-1 domain 59 end.
In parallel, the cDNA sequence corresponding to the a1 through
a3 domains of HLA-G1 was amplified by PCR with primers HLA-
G-a1_Mlu_Sph_F and HLA-G-a3_Xho_Sal_R (Table 1). This
removed the HLA-G peptide leader sequence and the stop codon.
The PCR fragments corresponding to B2M and the a1-a2-a3
domains of HLA-G were then digested with the Eag-I restriction
enzyme, purified, and ligated together. Mlu-I and Xho-I were then
used to insert the obtained B2M_a1-a2-a3 fusion sequence (B2M-
HLA-G1s) into a PGEMT/easy vector (Promega). The restriction
enzymes Age-I and Xho-I were used to transfer the B2M-HLA-G1s
sequence to the pFUSE-hFc1 (InVivogen, Toulouse, France) in
order to fuse B2M-HLA-G1s to the Fc part of a human IgG.
B2M-HLA-G5 (b2-microglobulin fused to the HLA-G5
heavy chain). To generate B2M fused to the heavy chain
of the HLA-G5 isoform, the pFUSE-B2M-HLA-G1s-Fc plas-
mid described above was used as template and amplified
with B2M_sig_TOPO_F and a3_i4_Xho_Stop_R (Table 1).
a3_i4_Xho_Stop_R contains the HLA-G intron 4 sequence that
replaces the transmembrane and intracellular and domains of
HLA-G1 in HLA-G5. The PCR fragment was then ligated into
the pcDNA 3.1 D/V.5-His-Topo vector (Invitrogen) using 3.1
Directional TOPOH Expression Kit (Invitrogen).
Alpha1-Fc (HLA-G alpha-1 domain fused to the Fc part of
a murine IgG). The cDNA sequence of HLA-G alpha-1
domain was amplified by PCR using the primers EcoRI_a1_F
and EcoRV_a1_R (Table 1). The EcoRI and EcoRV restriction
enzymes were used to insert the HLA-G alpha-1 coding sequence
into the pFUSE-mFc2 vector (Invivogen), fusing it to the secretion
sequence of IL-2 and a mouse IgG Fc fragment.
Alpha1_peptide (synthetic peptide corresponding to the
HLA-G alpha-1 domain). The peptide corresponding to the
alpha-1 domain of HLA-G was synthesized by Jerini, Berlin,
Germany.
Figure 1 is a schematic representation of the generated proteins
and peptides.
Cell culture and proteins production
For production of HLA-G fusion proteins, the HeLa human cell
line (ATCC) was transfected by the various plasmids using the
Lipofectamine
TM 2000 transfection reagent (Invitrogen) and kept
at 37uC, 5% CO2 in DMEM (Dulbco’s Modified EagleMedium
GIBCO) GlutaMAX
TM supplemented with 10% fetal calf serum
(GIBCO) and the appropriate selective antibiotics. For B2M-
HLA-G1s-Fc and Alpha1-Fc, zeocin
TM was used at a concentra-
tion of 500 mg/mL. For B2M-HLA-G5, geneticin was used at a
concentration of 1 mg/mL.
Table 1. Primers used for fusion protein generation.
B2M_Sig_Mlu-I_Sph-I_F 59 CGTCGCATGCACGCGTCGATGTCTCGCTCCGTGGCC 39
B2M-Link-a1_R 59 TCATGGAGTGGGAGCCGGATCCGCCACCTCCGGATCCGCCACCTCCGGATCCGCCACCTCCCATGTCTCGATCCCACTT 39
HLA-G-a1_Mlu_Sph_F 59 ACTGGCATGCACGCGTCGGGCTTCCACTCCATGA 39
HLA-G-a3_Xho_Sal_R 59 TATGGTCGACCTCGAGCGCAGCTGCCTTCCATCTCAGCATGAG 39
B2M_sig_TOPO_F 59 CACCATGTCTCGCTCCGTGGCC 39
a3_i4_Xho_Stop_R 59 ATCTTAACTCGAGAGGTCTTCAGAGAGGCTCCTGCTTTCC>TAACAGACATGATGCCTCCATCTCCCTCCTTACTCCATCTCAGCATGAG 39
EcoRI_a1_F 59 AAAGAATTCGGGCTCCCACTCCATGAGGT 39
EcoRV_a1_R 59 AAAGATATCCCACTGGCCTCGCTCTGGTTG 39
doi:10.1371/journal.pone.0021011.t001
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tants, cells were harvested after 48 hours. Supernatants were
filtered through 0.2 mM filter (Millipore) and then used as is, or
stored at 220uC.
HLA-G-specific ELISA
HLA-G-specific ELISAs were performed on cell culture
supernatants using Mem-G/09 (Exbio, Praha) as capture antibody
and anti-B2m as detection antibody as described [32]. Purified
HLA-G5 was used as standard protein. Samples were run as
duplicates and represented as mean+/2SEM.
Western-blot analysis
Immunoprecipitation. HLA-G-Fc proteins were immuno-
precipitated from cell culture supernatants using Protein G
sepharose beads (GE Healthcare). B2M-HLA-G5 fusion proteins
were immunoprecipitated from supernantants using anti-HLA-
G5-coated Protein G sepharose beads (clone 5A6, Exbio, Praha).
Supernatants of non-transfected cells were used as negative
controls. Immunoprecipitates were then washed three times with
16PBS and the proteins were eluted by incubation in Laemmli
buffer under reducing or non-reducing conditions, and boiled
before loading.
Western blots. Samples were loaded on polyacrylamide SDS-
PAGE gels and transferred onto Hybond nitrocellulose membranes
(Amersham Pharmacia Biosciences). Following blocking with 5%
non-fat milk in TBS/0,2% Tween 20, membranes were incubated
overnight with anti-HLA-G antibody (clone 4H84, Exbio, Praha),
and revealed using HorseRadish peroxydase-conjugated goat anti-
mouse secondary antibody. Membranes were revealed with the
ECL
+ detection system (Amersham Pharmacia Biosciences).
ILT2 NFAT-GFP reporter cell assay
NFAT-GFP reporter cells expressing the ILT2-PILRb chimera
were described previously [22]. The cell-surface expression of
ILT2-PILRb chimera was monitored by FACS staining with PE-
Cy5-conjugated ILT2-specific mAb (clone GHI/75, BD Biosci-
ences). In this system, GFP expression can be induced only upon
proper ILT2 receptor binding.
Mice
C57BL/6 and B6.C-H-2
bm12 (bm12) mice were purchased from
Jackson Laboratory. ILT4-transgenic mice have been described in
[21]. The use of animals for this work was approved by the animal
care committee of the Medical College of Georgia.
In vivo allograft experiments
The in vivo experimental procedures were approved by the
animal care committee of the Medical College of Georgia
(approval ID: BR08-06-070) and the experiments were conducted
in accordance with institutional guidelines for animal care and use.
For B2M-HLA-G1s-Fc and alpha1-Fc fusion proteins, 1610
8
sulfate latex beads 4%w/v 5 mm (Invitrogen) were coated with
20 mg/ml AffiniPure anti-human IgG Fc fragment or Goat Anti-
mouse, respectively (Jackson ImmunoResearch) for 2 hours at
37uC followed by a 2-hour incubation with BSA (2 mg/ml). After
Figure 1. Schematic representation of the generated proteins and their coding sequences. (A) B2M-HLA-G1s-Fc, (B) B2M-HLA-G5, (C)
Alpha1-Fc, (D) Alpha1_peptide. Arrows indicate the linker between beta-2-microglobulin and HLA-G alpha-1 domain.
doi:10.1371/journal.pone.0021011.g001
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fusion proteins at 4uC for 16 hours. Subsequently, the beads were
washed twice with PBS. 5 ml of HLA-G-Fc fusion proteins (1 mg/
ml) were used for 5610
6 sulfate latex beads. As a negative control,
sulfate latex beads were prepared in an identical manner except
that PBS or HeLa mock supernatant was used rather than
supernatants containing HLA-G-Fc fusion proteins.
For B2M-HLA-G5, beads were generated by grafting the anti-
HLA-G5 antibody 5A6 (Exbio, Praha) on beads prior to
incubation in B2M-HLA-G5-containing culture media.
For alpha1_peptide, beads were generated by direct coating
onto latex beads.
Sulfate latex beads (5610
6) were injected intraperitoneally on
the day before skin grafting. Specific pathogen-free C57BL/6 mice
and ILT4-transgenic mice (both H-2b, 8–10 weeks of age) were
used as skin graft recipients throughout the study. Recipient mice
received HLA-G-coupled latex beads, donor skin was from MHC
class II-disparate B6.CH-2bm12 (bm12, H-2b) mice. Allogeneic
skin grafts were performed by standard methods. Briefly, skin
(1.0 cm
2) from the tail of donor mice (12–14 weeks old) was grafted
onto the flank of recipient, anesthetized mice. The graft was
covered with gauze and plaster, which were removed on day 10.
Grafts were scored daily until rejection (defined as 80% of grafted
tissue becoming necrotic and reduced in size). All skin grafting
survival data were tested by Kaplan Meier Survival Analysis.
Results
Structural validation of the HLA-G recombinant proteins
We first investigated the conformation of the recombinant
proteins, focussing primarily on their monomeric/multimeric
status, and then on the conformation of the B2M-HLA-G fusion
proteins.
To investigate the monomeric/multimeric status of the engi-
neered proteins, these were immuno-precipitated using protein G-
Sepharose beads either directly (for Fc-containing proteins), or after
binding to anti-HLA-G5 mAb (for B2M-HLAG5). No immuno-
precipitation was required for alpha1_peptide. Proteins and peptide
were then analyzed by electrophoresis on non-reducing gels.
Figure 2A shows that Fc fusion proteins were present only as
dimers, and that B2M-HLA-G5 and alpha1_peptide also efficiently
formed multimers, even if some monomeric structures remained.
Thus, all generated proteins and peptide were capable of forming
dimers and/or multimers and found mainly as such.
We next investigated whether the B2M-HLA-G5 and B2M-
HLA-G1s-Fc fusion proteins were properly folded. For this, we
took advantage of the existence of an ELISA assay based on the
conformational anti-HLA-G antibody MEM-G/09 which recog-
nizes only HLA-G folded in combination with B2M. We
performed conformational ELISA on supernatants which con-
tained similar amounts of B2M-HLA-G1s-Fc, B2M-HLA-G5,
using purified HLA-G5 protein as standard. Figure 2C shows
these similar amounts of B2M-HLA-G1s-Fc, B2M-HLA-G5, and
HLA-G5 control protein, were detected by conformational ELISA
with similar efficiency. This means that the (GSSS)62 spacer
linking B2M and HLA-G heavy chain did not alter the
B2M:HLA-G conformation. These results are in agreement with
a previous study on a similarly produced B2M-HLA-A2 fusion
protein [33]. The absence of conformational antibodies for the
alpha-1 domain of HLA-G prevented a similar investigation for
the alpha1-Fc construct.
Thus, B2M-HLA-G5, B2M-HLA-G1s-Fc, and alpha1-Fc were
dimerized, properly folded (B2M-HLA-G5 and B2M-HLA-G1s-
Fc), and thus, potentially capable of being functional.
In vitro binding to ILT2
In vitro, the inhibitory effect of HLA-G is mainly due to its
interaction with ILT2, as shown by HLA-G:ILT2 interaction
blocking experiments [20]. Furthermore, it was reported that
ILT2 binds primarily to dimers of B2M-associated HLA-G
molecules, but not to monomers [22,34]. Thus, we investigated
the capability of B2M-HLA-G5 and B2M-HLA-G1s-Fc proteins
to bind and activate ILT2. For this, we used an ILT2 NFAT-GFP
reporter cell assay in which HLA-G binding to, and activation of
ILT2 leads to GFP expression [22]. The results in Figure 3 show
that B2M-HLA-G5 and B2M-HLA-G1s-Fc molecules induced
GFP expression, i.e. ILT2 activation. Thus, these two molecules
had the potential of being functional. Alpha1-Fc and alpha1_pep-
tide were not investigated, since it is known that ILT2 does not
bind HLA-G through its alpha-1 but through its alpha-3 domain
[35].
In vivo function of recombinant HLA-G molecules
HLA-G promotes skin allograft survival in mice [30]. This has
been demonstrated by immunization of wild type and ILT4-
transgenic graft recipients mice with recombinant HLA-G
24 hours prior to skin grafting [21,31]. In these experiments,
HLA-G was provided as recombinant soluble HLA-G1 produced
in bacteria, refolded with B2M, and then tetramerized prior to be
coated onto latex beads. In the current study, HLA-G was
provided as B2M-HLA-G5 bound to anti HLA-G5-coated beads
(5A6 mAb), B2M-HLA-G1s-Fc bound to anti-Fc-coated beads,
alpha1-Fc bound to anti-Fc-coated beads, and alpha1_peptide
covalently bound to beads (B2M-HLA-G5 beads, B2M-HLA-G1s-
Fc beads, alpha1-Fc beads, and alpha1_peptide beads, respective-
ly). Control beads were mAb-coated beads alone (no HLA-G) or
non-coated beads (control for alpha1_peptide beads).
The results obtained in the case of a MHC class II-disparate
B6.C-H-2
bm12 (bm12) to C57BL/6 allogeneic skin transplantation
are shown in Figure 4A. Immunization of the recipient with mAb-
coated control beads prior to transplantation had no effect on
allograft survival, ruling out any effect of the beads or animal
manipulation on the results (not shown). However, all recombi-
nant HLA-G proteins proved to be tolerogenic. B2M-HLA-G5
beads were the most efficient and increased the median graft
survival time from 18 to 29 days (n=9, p=0.0001). By
comparison, B2M-HLAG1s-Fc beads were less efficient but still
increased the median graft survival time from 18 to 23 days (n=8,
p=0.055). Alpha1-Fc beads prolonged skin allograft median
survival time, from 18 to 29 days (n=10, p=0.001), but by
comparison, alpha1_peptide-coated beads were less efficient,
increasing the median graft survival from 20.5 to 22 days only
(n=9, p=0.0081). These results demonstrate an inhibitory effect
observed in vivo for all fusion proteins and for alpha1_peptide. It is
surprising that B2M-HLA-G5 was more efficient than B2M-HLA-
G1s-Fc, since these two molecular constructs have the same B2M-
HLA-G sequence. It is even more surprising to observe a
tolerogenic effect of alpha1-Fc molecules and alpha1_peptide.
Indeed, it is known that HLA-G-induced increased survival of skin
allograft time is mediated through PIR-B [31], which shares
sequence similarities with ILT molecules, and in particular with
ILT4. However, ILT4 binds HLA-G through its alpha-3 domain,
but does not recognize its alpha-1 domain [36].
Thus, to investigate this issue, we evaluated the tolerogenic
function of B2M-HLA-G5 and alpha1-Fc recombinant proteins
using ILT4-transgenic mice as skin allograft recipients. B2M-
HLA-G5 and Alpha1-Fc were chosen because they were the two
most efficient B2M-HLA-G and alpha1 structures.
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e21011Figure 2. Monomeric/multimeric status and conformation of recombinant proteins. A Monomeric/multimeric status of recombinant
proteins. Western blot analysis of recombinant proteins immunoprecipitated from supernatants of HeLa B2M-HLA-G1s-Fc, HeLa Alpha1-Fc, HeLa B2M-
HLA-G5, and of alpha1_peptide. B Quantification of B2M-HLA-G5 and B2M-HLA-G1s-Fc proteins. Western blot analysis of recombinant B2M-HLA-G5 and
B2M-HLA-G1s-Fc proteins immunoprecipitated from cell culture supernatants. Purified HLA-G5 recombinant protein was used as quantification
standard. C Conformation of B2M-HLA-G5 and B2M-HLA-G1s-Fc proteins. Recombinant HLA-G5 protein was used as a standard in HLA-G-specific ELISA.
Curves represent the concentration of the proteins properly folded into the supernatant according to the dilution.
doi:10.1371/journal.pone.0021011.g002
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retained its tolerogenic function, increasing the median graft
survival time from 17 to 24.5 days (n=8, p=0.0004), whereas
alpha1-Fc did not (n=10, p=0.039).
Discussion
In this work, we investigated the tolerogenic properties of HLA-
G recombinant proteins. These were B2M-HLA-G heavy chain
fusions and HLA-G alpha-1 domains dimerized either through an
Fc fragment, or naturally through a C42-C42 disulfide bond. Of
note, because of the presence of B2M and the linker in our
constructs, the cysteines involved in HLA-G homodimerization
were no longer in position 42, but for the sake of clarity, we kept
calling C42 the cysteines of the HLA-G alpha-1 domain that are
responsible for homodimerization.
Our first aim was to evaluate the tolerogenic function of two
types of single-chain B2M-HLA-G homodimers. In this study, we
showed that all generated proteins and peptide were multi-
merized. Furthermore, B2M-HLA-G fusions were properly
folded and could bind and activate the ILT2 receptor. These
data also showed that with respect to binding to and signaling
through ILT receptors, dimerization through C42-C42 disulfide
bonding or Fc did not seem to matter. This seemed to be
confirmed by in vivo data, which showed that both dimer types
were functional. Yet, B2M-HLA-G5 was more efficient than
B2M-HLA-G1s-Fc, and alpha1-Fc was more efficient than
alpha1_peptide in vivo. It is possible that Fc-dimers and natural
dimers might not be structurally identical: whereas dimers
formed via C42-C42 bonds are likely to closely resemble
‘‘natural’’ HLA-G dimers, dimers formed via Fc might not. As
far as HLA-G structure is concerned, B2M-HLA-G1s-Fc dimers
might actually be two HLA-G monomers next to each other
rather than ‘‘real’’ HLA-G dimers, although additional dimer-
ization through the C42 residues of HLA-G molecules cannot be
ruled out and might happen through the C42 of B2M-HLA-G1s-
Fc HLA-G portions located within the same homodimer or not.
The same hypothesis can be made for alpha1 constructs:
alpha1_peptides may only dimerize through C42-C42 disulfide
bridging, whereas alpha1-Fc proteins may multimerize further.
Our data seem to indicate that for B2M-HLA-G structures,
natural multimers are more efficient than Fc-multimers (B2M-
HLA-G structures), and that multimers are more efficient than
dimers (alpha1 structures). Whether this will hold true when
soluble HLA-G multimers and not bead-bound multimers are
used is currently under investigation.
It was reported that all isoforms of HLA-G have immuno-
suppressive functions [16], including HLA-G3 which extracellu-
lar part is constituted of the alpha-1 domain only and which was
shown to block the functions of NK cells and CTLs. The other
goal of this study was to determine if tolerance induction in vivo
could be induced by the alpha-1 domain of HLA-G only. For
this purpose, alpha1-Fc molecules and a synthetic peptide of
HLA-G alpha-1 domain were produced. Alpha1-Fc molecules
multimerized, whereas alpha1_peptide molecules dimerized.
Interestingly, in vivo data showed that the alpha-1 domain of
HLA-G prolonged the survival of allo-transplanted skin in mice.
This was especially true of alpha1-Fc molecules. Once again, this
was unexpected because HLA-G-induced tolerance in mice is
mediated through HLA-G binding to PIR-B. This receptor
shares sequence similarity with the human ILT family of
molecules, and particularly with ILT4 which is known to bind
HLA-G alpha-3 domain. One explanation for this could be that
when it is not part of the HLA-G1:B2M:peptide complex, the
HLA-G alpha-1 domain adopts a conformation that allows it to
bind to PIR-B, in which case it might also bind ILT molecules.
One other explanation could be that HLA-G alpha-1 domain
cross-reacts with inhibitory molecules other than PIR-B, such as
murine KIRs for instance. In order to discriminate between
these two hypotheses, we tested B2M-HLA-G5 and alpha1-Fc in
skin transplantation experiments in which the recipient was an
ILT4-transgenic mouse. In these experiments, B2M-HLA-G5
retained its tolerogenic capability, whereas alpha1-Fc almost lost
it all. It remains unclear why alpha1-Fc was less tolerogenic in
ILT4-transgenic mice than in wild type mice, given that their
background was identical, although one can hypothesize that
ILT4 may have behaved as a dominant positive PIR-B
homologue, thus functionally replacing it. Regardless of the
reason, these data clearly show that alpha1-Fc was unable to
function through ILT4, whereas B2M-HLA-G5 could. Thus, the
originally observed tolerogenic function of alpha1-Fc in vivo was
most likely due to a specific interaction with PIRB that does not
happen with ILT4, or to a cross-reaction with a murine receptor
other than PIR-B, indicating that HLA-G alpha1 multimers may
function through other receptors than ILT molecules.
KIR2DL4, a HLA-G specific receptor which is supposed to
bind the alpha-1 domain of HLA-G was not present in our
system (no shown) and was also ruled out. Consequently, the
mechanism by which HLA-G alpha1 multimers function
remains unknown for lack of a receptor, which weakens its
position as a candidate tolerogenic molecule to be used in human
beings.
Nevertheless, it remains that the alpha-1 domain of HLA-G is
present on all HLA-G isoforms. In the light of the data gathered,
we propose that one of the main functions of the alpha-1 domain
Figure 3. ILT2-mediated signaling by B2M-HLA-G5 and B2M-
HLA-G1s-Fc proteins. NFAT-GFP reporter cells expressing the ILT2-
PILRb chimera were stimulated for 16 h with 1.5 mg/ml of the indicated
HLA-G recombinant proteins. Non-treated reporter cells were used as
negative control, and tetrameric complexes of HLA-G1 (HLA-G1t, [31])
were used as positive control. GFP expression on reporter cells was
analyzed by flow cytometry. Numbers indicate the percentage of GFP-
positive cells. Data shown are from one of four independent
experiments.
doi:10.1371/journal.pone.0021011.g003
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inhibition, but to induce dimerization, which is required for
ILT binding and for proper function. In this context, it seems that
the most stable and active forms of HLA-G might indeed be
B2M-associated HLA-G1/-G5, or, as an alternative possibility,
HLA-G2/-G6 dimers, containing only the alpha-3 domain
required for ILT binding and the alpha-1 domain necessary for
dimerization.
In this study, we have demonstrated the tolerogenic properties
of artificial single-chain B2M:HLA-G dimers in vivo in the context
of allogeneic skin transplantation. In vivo tolerization was achieved
according to a protocol developed with refolded B2M:HLA-G
tetramer-coated beads. Apparently, the B2M-HLA-G structures
presented here did not perform better than refolded ones.
However, it has to be noted that tolerization was obtained by a
single injection of HLA-G-coated beads, which is an impressive
tolerogenic effect. The advantage of dimerized B2M-HLA-G
single-chains over refolded HLA-G tetramers might come from
increased stability, which would allow for a longer tolerogenic
effect and better prospects for use as soluble molecules rather than
coated on beads. The suitability of these constructs for tolerance
induction, as well as their in vivo stability are currently under
investigation.
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Figure 4. Tolerogenic function of HLA-G fusion proteins and peptide. A. C57BL/6 mice strongly recognize the MHC class II-disparate mutant
bm12 mouse that carries the I-Abm12 alloantigen. The capability of HLA-G-coated beads to delay rejection was evaluated. Control treatment (dotted
lines): beads coated with mAb but without HLA-G proteins. Results are expressed as Median of graft survival time. Kaplan-Meier curves representing
graft survival are shown for each HLA-G protein/peptide for controls (plain lines). Associated values are indicated as a table underneath the curves. B.
The same experiments were performed using ILT4-transgernic mice as skin graft recipients, and for Alpha1-Fc and B2M-HLA-G5. Tables: Median
survival of transplant, number of animals, and significance are indicated below the corresponding survival graphs.
doi:10.1371/journal.pone.0021011.g004
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